The 30m figure is certainly small and they have another product in development with a partner that is around the 20m mark.
Management have pointed out that the margins/royalty for acrux is high, but I still don't think these 2 products will be significant earners.
Perhaps the idea is the make the 3-5m back over time and also they will have an established relationship for future generics which might fit into Dash.
ACR Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
